VCRE

Vicore Pharma ABdistress 1/10 · well-funded / low risk

$11.620%today-28% from 52w high

vicorepharma.com40 employeesFounded 2000Stockholm, SwedenBiotechnology

Lead: Idiopathic Pulmonary Fibrosis (IPF) · est. market ~$5B (approx, global)

Revenue

pre-revenue

Liquidity

$1060M

Runway

2.8 yrs

Shares 1y

—

Price & events

-28.5% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.3%

-6.1%

—

-28.5%

All

Overview

Volume: 1.70K
52 Week Range: $11.44 – $16.25
Float Shares: 198.62M
RVOL: 0.02x
Beta: 0.15

Pipeline stages · 1 programs

Buloxibutid

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-05

Pipeline · 1 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-05 Estimated 50% readout ~2027-06-15	Phase 2	Buloxibutid	Idiopathic Pulmonary Fibrosis (IPF)	—	active not recruiting

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: — · 0 offerings/1y · 0 PIPEs

none

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — Idiopathic Pulmonary Fibrosis (IPF)

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.